...
首页> 外文期刊>Journal of Surgical Oncology >Prevention of complications following pelvic exenteration with the use of mammary implants in the pelvic cavity: Technique and results of 28 cases.
【24h】

Prevention of complications following pelvic exenteration with the use of mammary implants in the pelvic cavity: Technique and results of 28 cases.

机译:通过在盆腔中使用乳腺植入物预防盆腔移出术后的并发症:28例技术和结果。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: With the evolution of neo-adjuvant therapy and the introduction of peritonectomy with chemotherapy in surgical practice, pelvic exenteration has taken second place in the treatment of advanced pelvic tumors. This surgery remains the first of choice for the treatment of T4 superior and medium rectal tumors that are not susceptible to neo-adjuvant radiochemotherapy, for uterine tumors and cervical FIGO IV T4, for pelvic recurrence and for T4 bladder tumors. After a pelvic exenteration the pelvic cavity becomes occupied by the intestinal loops, causing an increase in the risk of short and long-term complications such as radiation enteritis in the case of post-operative radiotherapy, occlusions, and enteric fistulas that could be avoided by isolating the small intestine in the pelvic cavity. METHODS: With this aim we positioned a mammary prosthesis (implant) in the cavity of the last 28 cases we treated, and did not observe complications related to the prosthetic implant. RESULTS: No early or delayed complications, such as occlusions or fistulas, were observed. All the patients treated underwent adjuvant radiotherapy with no evidence of radiation enteritis. Ten patients were recanalized with removal of the implant, ultra-low rectal anastomosis was performed in six cases and colo-anal anastomosis was performed in four cases. Eight patients were not recanalized, six distance due to recurrence and two local recurrence. Nine patients are currently in follow-up, disease free between 1 and 12 months. CONCLUSIONS: We retain the encouraging results observed that the use of mammary implants in the pelvic cavity after pelvic exenteration should be part of the cultural patrimony of the surgeon who approaches this type of major radical surgery.
机译:背景:随着新辅助疗法的发展以及在外科手术中采用化学疗法进行腹膜切除术,盆腔积液在晚期盆腔肿瘤的治疗中已排名第二。对于不易接受新辅助放化疗的T4上中直肠肿瘤,子宫肿瘤和宫颈FIGO IV T4,骨盆复发和T4膀胱肿瘤,该手术仍是首选治疗方法。盆腔脱离后,盆腔被肠loop占据,导致短期和长期并发症的风险增加,例如在术后放疗,放射线闭塞和肠瘘等可以避免的情况下,可能是放射性肠炎。分离盆腔中的小肠。方法:为了这个目的,我们将乳房假体(植入物)放置在我们所治疗的最后28例患者的腔中,并且没有观察到与假体相关的并发症。结果:未观察到早期或延迟并发症,如阻塞或瘘管。所有接受治疗的患者均接受了辅助放疗,没有放射性肠炎的迹象。十例患者在去除种植体的情况下再次进行了根管再造术,其中6例进行了超低位直肠吻合术,而4例进行了结肠肛门吻合术。 8例患者未再行根管治疗,其中6例因复发而未行再根管治疗,两次局部复发。目前有9名患者正在接受随访,并且在1到12个月之间没有疾病。结论:我们保留令人鼓舞的结果,观察到在盆腔脱离后在盆腔中使用乳腺植入物应该是这种类型的主要根治性手术的外科医生的文化遗产。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号